Deja Vu ,again "In January 2022, Syneos Health (NASDAQ: SYNH) filed an arbitration proceeding against FSD Pharma claiming that the Company owed Syneos Health (NASDAQ: SYNH) USD$3,915,388.69 in damages and interest on that amount for a failed Phase II FDA trial for FSD 201. Syneos Health (NASDAQ: SYNH) also sought an order requiring FSD to pay its legal expenses.
The trial originally required the enrollment of 350 patients in North America; the geographic scope was later expanded to include several South American countries and 35 sites in total (25 in N. America and 10 in S. America)."
Why is it that every new business initiative ends up being a failure or ends up in a lawsuit.
From the failed cannabis venture, steady state, growing cannabis from seaweed, PEA Covid, PEA for IBD, now this
Cmon guys... Do I see a movie on Netflix ?